330 related articles for article (PubMed ID: 17764782)
1. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia.
Fasano CJ; O'Malley G; Dominici P; Aguilera E; Latta DR
Ann Emerg Med; 2008 Apr; 51(4):400-6. PubMed ID: 17764782
[TBL] [Abstract][Full Text] [Related]
2. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia.
Francis M; Langhan T; Prosser J; Hoffman R
Ann Emerg Med; 2008 Jun; 51(6):795-6; author reply 796-7. PubMed ID: 18489980
[No Abstract] [Full Text] [Related]
3. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure.
Vallurupalli S
Ann Pharmacother; 2010 Feb; 44(2):387-90. PubMed ID: 20118140
[TBL] [Abstract][Full Text] [Related]
4. [Role of octreotide in the treatment of hypoglycemia induced by sulfonylureas].
Clerc D; Hugli O; Trueb L; Yersin B
Rev Med Suisse; 2008 Aug; 4(167):1764-7. PubMed ID: 18800755
[TBL] [Abstract][Full Text] [Related]
5. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
Rosak C; Haupt E; Walter T; Werner J
Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
[TBL] [Abstract][Full Text] [Related]
6. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
7. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
Holstein A; Hahn M; Stumvoll M; Kovacs P
Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
[TBL] [Abstract][Full Text] [Related]
8. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
9. Hypoglycemia in hospitalized patients treated with sulfonylureas.
Deusenberry CM; Coley KC; Korytkowski MT; Donihi AC
Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146
[TBL] [Abstract][Full Text] [Related]
10. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses.
Boyle PJ; Justice K; Krentz AJ; Nagy RJ; Schade DS
J Clin Endocrinol Metab; 1993 Mar; 76(3):752-6. PubMed ID: 8445035
[TBL] [Abstract][Full Text] [Related]
11. Octreotide for sulfonylurea-induced hypoglycemia following overdose.
Carr R; Zed PJ
Ann Pharmacother; 2002 Nov; 36(11):1727-32. PubMed ID: 12398568
[TBL] [Abstract][Full Text] [Related]
12. Octreotide: an antidote for sulfonylurea-induced hypoglycemia.
McLaughlin SA; Crandall CS; McKinney PE
Ann Emerg Med; 2000 Aug; 36(2):133-138. PubMed ID: 10918104
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study.
Rave K; Flesch S; Kühn-Velten WN; Hompesch BC; Heinemann L; Heise T
Diabetes Metab Res Rev; 2005; 21(5):459-64. PubMed ID: 15915547
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the use and safety of octreotide as antidotal therapy for sulfonylurea overdose in children.
Dougherty PP; Lee SC; Lung D; Klein-Schwartz W
Pediatr Emerg Care; 2013 Mar; 29(3):292-5. PubMed ID: 23426239
[TBL] [Abstract][Full Text] [Related]
15. Octreotide therapy for nateglinide-induced hypoglycemia.
Sherk DK; Bryant SM
Ann Emerg Med; 2007 Dec; 50(6):745-6. PubMed ID: 18023765
[No Abstract] [Full Text] [Related]
16. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas.
Shorr RI; Ray WA; Daugherty JR; Griffin MR
Arch Intern Med; 1997 Aug 11-25; 157(15):1681-6. PubMed ID: 9250229
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
18. [Evaluating the feature of hypoglycemia detected by continuous glucose monitoring system during temporary continuous subcutaneous insulin infusion in type 2 diabetes patients].
Li M; Zhou J; Bo YQ; Lu W; Jia WP; Xiang KS
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1679-82. PubMed ID: 19024537
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
20. [Successful treatment of severe sulfonylurea-induced hypoglycemia by the subcutaneous administration of octreotide in an elderly patient with diabetes: A case report].
Nakaya M; Oka R; Miyamoto S
Nihon Ronen Igakkai Zasshi; 2019; 56(3):336-342. PubMed ID: 31366755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
